Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine Pharmaceuticals' prior multi-center, single-arm, Phase II trial investigating bavituximab in conjunction with docetaxel in patients suffering from locally advanced or metastatic breast cancer showed 20.7 month median overall survival (OS).
Subscribe to our email newsletter
The trial evaluated patients with locally advanced or metastatic breast cancer who had received one prior chemotherapy regimen were treated with weekly bavituximab and docetaxel.
In a separate published study included in the docetaxel package insert, median OS was 11.7 months for metastatic breast cancer patients treated with docetaxel alone.
Peregrine Medical Oncology Kerstin Menander said this latest data point from the prior Phase II signal-seeking trials is encouraging, and shows adding bavituximab to the standard chemotherapy docetaxel offers meaningful survival benefits to breast cancer patients.
""We are eager to complete patient enrollment in our two randomized Phase II trials in non-small cell lung cancer to assess further bavituximab’s potential in combination with chemotherapy for advanced cancer patients," Menander said.